Argenx SE ADR (ARGX) reported Thursday it swung to Q3 net profit of $1.39 per diluted share from $1.25 loss per share a year earlier.
Total operating income for the quarter ended Sept. 30 was $588.9 million, up from $339.8 million a year earlier.
The Dutch immunology company said with an increase in cash, cash equivalents and current financial assets in the quarter and year-to-date, the previously issued cash guidance no longer applies.
The financial guidance on the combined selling, general and administrative expenses and research and development expenses remains unchanged at approximately $2 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.